阿斯利康和安进公司联合公布了Tezspire用于治疗慢性鼻窦炎伴鼻息肉的3期试验的主要结果，显示该治疗显著缩小了患者的鼻息肉大小，并减轻了鼻塞症状。试验的积极结果表明该药有望成为这种疾病的新治疗选择。 慢性鼻窦炎伴鼻息肉是一种复杂的炎症性疾病 ...

▎药明康德内容团队编辑日前，阿斯利康（AstraZeneca）与安进（Amgen）合作开发的“first-in-class”单抗Tezspire（tezepelumab）针对伴有鼻息肉的慢性鼻窦炎（CRSwNP）患者进行的WAYPOINT临床3期试验 ...

在最新的试验结果中，Tezspire治疗组展现出了统计学和临床意义上显著的改善，这标志着在慢性鼻窦炎及鼻息肉治疗方法上的一大突破。这项研究结果为进一步的临床应用奠定了基础，同时也为医务人员提供了新的武器，以更有效地帮助患者。

Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

公开资料显示，Tezepelumab是阿斯利康与安进共同开发的一款first-in-class单克隆抗体，可抑制胸腺基质淋巴细胞生成素 (TSLP)。TSLP是一种关键的上皮细胞因子，位于多种炎症级联反应的上游，与哮喘、CRSwNP、慢性阻塞性肺疾病 ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

特拉华州威尔明顿 - 阿斯利康制药和安进公司宣布,TEZSPIRE(tezepelumab)用于治疗严重慢性鼻窦炎伴鼻息肉患者的III期WAYPOINT试验取得积极结果,与安慰剂相比,显著减少了息肉大小和鼻塞症状。 该试验涉及有症状的成年严重慢性鼻窦炎伴鼻息肉(CRSwNP)患者,这些患者接受标准治疗但仍有症状。TEZSPIRE以双盲方式皮下给药,对照组为安慰剂。 试验的共同主要研究者Joseph ...

WILMINGTON, Del., November 08, 2024--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) ...

Alliance revenues included $361 million from Daiichi Sankyo for Enhertu and $123 million of AstraZeneca’s share of gross ...